By Fineline Cube Peijia Medical Ltd. (HKG: 9996) announced an exclusive distribution agreement with B. Braun Melsungen AG for the SeQuent Please CIS, a paclitaxel drug-coated intracranial balloon dilatation catheter, in mainland China. The partnership grants Peijia exclusive rights to commercialize B. Braun’s innovative “no-implant” therapy for intracranial vascular diseases, leveraging B. Braun’s established drug-coated balloon (DCB) technology to address the significant unmet need in China’s cerebrovascular intervention market. The product has been filed for marketing approval in China and is specifically engineered for the slender and tortuous anatomy of intracranial vessels.
Partnership Details
| Item | Detail |
|---|---|
| Parties | Peijia Medical Ltd. (HKG: 9996) and B. Braun Melsungen AG |
| Product | SeQuent Please CIS – paclitaxel drug-coated intracranial balloon |
| Territory | Exclusive distribution rights for mainland China |
| Technology Platform | B. Braun’s established drug-coated balloon (DCB) technology |
| Regulatory Status | Marketing application filed with NMPA |
| Therapeutic Approach | “No-implant” treatment for intracranial vascular diseases |
| Announcement Date | 01 Jun 2026 |
Product Profile & Clinical Innovation
- Mechanism of Action: Precisely releases paclitaxel (anti-proliferative drug) onto diseased vessel walls during mechanical dilation of target lesions
- Primary Benefit: Effectively inhibits intimal hyperplasia and reduces long-term risk of restenosis
- Anatomical Optimization: Specifically designed to accommodate the slender and tortuous characteristics of intracranial vessels
- Therapeutic Paradigm: Provides innovative “no-implant” alternative to permanent stents, eliminating long-term complications associated with metallic implants
- Clinical Target: Intracranial atherosclerotic disease (ICAD), a leading cause of stroke in Asian populations
Strategic Market Implications
The exclusive distribution agreement positions Peijia to address China’s substantial cerebrovascular disease burden, where intracranial atherosclerosis accounts for approximately 30–50% of ischemic strokes compared to 8–10% in Western populations:
- Market Opportunity: China’s neurointerventional market projected to reach ¥15–20 billion ($2.1–2.8 billion) annually by 2028
- Unmet Need: Limited treatment options for intracranial vascular disease, with current therapies carrying high restenosis rates
- Competitive Advantage: First drug-coated balloon specifically designed for intracranial applications in the Chinese market
- Clinical Impact: Potential to significantly reduce stroke recurrence rates and improve patient outcomes
“This exclusive partnership with B. Braun represents a strategic expansion of our neurointerventional portfolio into innovative drug-delivery technologies,” said Dr. Li Chen, Chief Executive Officer of Peijia Medical. “SeQuent Please CIS addresses a critical gap in China’s stroke prevention landscape, offering neurointerventional specialists a sophisticated ‘no-implant’ solution specifically designed for our patients’ unique anatomical characteristics.”
Commercial Outlook & Competitive Positioning
Peijia’s established commercial infrastructure provides immediate market access advantages:
- Distribution Network: Leverages existing relationships with 500+ neurointerventional centers across China
- Physician Training: Comprehensive educational programs to support adoption of novel DCB technology
- Pricing Strategy: Premium positioning reflecting clinical innovation and improved patient outcomes
- Regulatory Pathway: Benefits from China’s accelerated review processes for innovative medical devices addressing unmet needs
Industry analysts view the deal as transformative for Peijia, establishing the company as a leader in advanced cerebrovascular interventions while providing B. Braun with optimal market penetration through a specialized local partner.
Forward‑Looking Statements
This brief contains forward-looking statements regarding distribution agreements, regulatory approvals, and market opportunities for SeQuent Please CIS. Actual results may differ due to NMPA review outcomes, market adoption patterns, and competitive dynamics.-Fineline Info & Tech